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Abstract
Background: Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection,
but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an
adenoviral vaccine vector in volunteers without prior immunity, we evaluated a recombinant replication-defective
adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, in a
randomized, double-blind, dose-escalation, multicenter trial (HVTN study 054) in HIV-1-seronegative participants without
detectable neutralizing antibodies (nAb) to the vector. As secondary outcomes, we also assessed T-cell and antibody
responses.
Methodology/Principal Findings: Volunteers received one dose of vaccine at either 10
10 or 10
11 adenovector particle units,
or placebo. T-cell responses were measured against pools of global potential T-cell epitope peptides. HIV-1 binding and
neutralizing antibodies were assessed. Systemic reactogenicity was greater at the higher dose, but the vaccine was well
tolerated at both doses. Although no HIV infections occurred, commercial diagnostic assays were positive in 87% of
vaccinees one year after vaccination. More than 85% of vaccinees developed HIV-1-specific T-cell responses detected by
IFN-c ELISpot and ICS assays at day 28. T-cell responses were: CD8-biased; evenly distributed across the three HIV-1
antigens; not substantially increased at the higher dose; and detected at similar frequencies one year following injection.
The vaccine induced binding antibodies against at least one HIV-1 Env antigen in all recipients.
Conclusions/Significance: This vaccine appeared safe and was highly immunogenic following a single dose in human
volunteers without prior nAb against the vector.
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Introduction
Approximately 2.7 million persons become infected with the
human immunodeficiency virus (HIV-1) each year [1]. Although a
recent clinical trial in Thailand found that a non-replicating
canarypox vector vaccine combined with an envelope protein
antigen may have provided limited protection [2], no vaccine has
yet been shown to be highly effective in preventing HIV infection
in humans. In non-human primate models, gene-based immuni-
zation with viral vectors, alone or in combination with DNA
plasmid vaccines, have protected against infection or disease
progression following challenge with immunodeficiency retrovi-
ruses; such protection is associated with the induction of
immunodeficiency virus-specific T-lymphocyte responses [3,4,
5,6,7], particularly CD8
+ T-cell responses. Accordingly, HIV-1
vaccine development efforts in recent years have focused on
recombinant viral vectors containing HIV-1 transgenes, alone or
in combination with HIV-1 DNA plasmid vaccines or protein
antigens.
The NIAID Vaccine Research Center’s recombinant adenovi-
rus 5 (rAd5) HIV-1 vaccine VRC-HIVADV014-00-VP was
previously tested in a dose-escalation clinical trial that found local
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13579and systemic signs and symptoms increase in frequency and
severity with increasing vaccine doses up to 10
11 particle units
(PU), but found no reactions of greater than moderate (grade 2)
severity. Although that study did not stratify enrollment by prior
Ad5 neutralizing antibody (nAb) titer, HIV-1-specific CD4
+ and
CD8
+ T-cell responses tended to be of lower magnitude in the Ad5
nAb seropositive participants [8].
Although seroprevalence varies widely from one area to
another, a substantial proportion of the world population has
evidence of immunity to Ad5, including approximately 80% of
adults in sub-Saharan Africa [9,10,11,12]. We hypothesized that
reactogenicity would be maximal and immunogenicity would be
optimal in the absence of pre-existing nAb against the vector.
Accordingly, to further investigate the safety and define the highest
tolerable dose of this vaccine in Ad5 nAb-seronegative individuals,
we performed a multicenter, randomized, double-blind, placebo-
controlled clinical trial of a single intramuscular dose of VRC-
HIVADV014-00-VP delivered at each of two escalating doses
(10
10 and 10
11 PU) in participants with undetectable (,1:12) titers
of pre-existing Ad5 nAb. This study therefore evaluated the
highest manufacturable dose of this rAd5 vector for safety and also
characterized its immunogenicity by evaluating vaccine-induced
T-cell responses against peptide pools reflecting diverse viral
isolates, as well as HIV-1 binding and neutralizing antibody
responses.
The primary (safety) objective was to characterize the safety and
tolerability of a single dose of the adenoviral vector vaccine
delivered at each of the two escalating doses in participants with
low (,1:12) titers of pre-existing Ad5 neutralizing antibodies.
The secondary immunogenicity objective was to evaluate the
HIV-specific immunogenicity of a single dose of the adenoviral
vector vaccine delivered at each of the two escalating doses, as
assessed by IFN-c ELISpot, Intracellular Cytokine Staining (ICS),
HIV-1-binding antibodies, and neutralizing antibody assays.
Methods
Ethics Statement
The study protocol was approved by institutional review boards
at each of the participating sites: Fred Hutchinson Cancer
Research Center IRB for the Seattle, WA site; Vanderbilt
University IRB for the Nashville, TN site; and University of
California San Francisco Committee on Human Research for the
San Francisco, CA site. All study participants provided written
informed consent prior to participation. The protocol for this trial
and supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1. The trial is
registered at ClinicalTrials.gov, registration NCT00119873.
Participants
Forty-eight male and female study participants were enrolled by
clinical staff at three HIV Vaccine Trials Network (HVTN) sites in
the United States (Seattle, WA; San Francisco, CA; and Nashville,
TN; 16 participants per site). A large pool of subjects was assessed
for eligibility for multiple HVTN clinical trials, with candidates
offered the opportunity to participate in a study for which they met
inclusion criteria. For this study, those criteria included age 18-50
years, good general health, completion of a questionnaire assessing
understanding of the study and the nature of participation, and
being willing and able to provide informed consent. Laboratory
inclusion criteria, tested within eight weeks prior to study
enrollment, included negative HIV-1 serum antibody test; AST,
ALT, alkaline phosphatase, total bilirubin, and creatinine within
institutional upper limits of normal; negative blood tests for
chronic hepatitis B and C; blood counts within normal range; and
Ad5 nAb titer ,1:12. Pregnant women were excluded.
Study Procedures
All participants received a single injection of either adenovector
vaccine VRC-HIVADV014-00-VP or buffer placebo, according
to randomized treatment assignment, as a 1 ml intramuscular
injection in the deltoid on the day of enrollment. The
randomization sequence was obtained by computer-generated
random numbers and provided to each site by a central data
monitoring center. Randomization was done sequentially for each
dose group and in blocks within the dose groups. The pharmacist
at each site with responsibility for dispensing the appropriate
vaccine was responsible for maintaining the security of the
randomization code and did not participate in clinical assessment
of participants. Participants in Group 1 received a 10
10 PU dose of
the study vaccine (n=20) or placebo (n=4). After a planned
review of safety data on all Group 1 participants, enrollment was
initiated in Group 2, in which participants received a 10
11 PU dose
of the study vaccine (n=20) or placebo (n=4). Figure 1 shows a
CONSORT Statement flow chart of study enrollment, allocation
and analysis [13].
Study clinicians and participants were blinded to the identity
(vaccine versus placebo) of study injections. To avoid unblinding
due to potential differences in appearance between vaccine and
placebo products, the pharmacists placed a yellow overlay over
each syringe before dispensing it to study clinicians. To avoid
possible unblinding by vaccine-induced anti-HIV antibodies,
participants were counseled throughout the trial not to obtain
HIV testing outside of the research units, which provided HIV
testing through a central laboratory using an algorithm that
distinguishes between vaccine-induced seropositivity and actual
HIV infection while preserving blinding of participants and site
staff.
Participants were evaluated by a study clinician following
vaccination, and each participant was instructed to record oral
temperature and any symptoms in a standardized written log for at
least three days; symptoms present on day 3 were followed to
resolution. Injection-site symptoms (pain, tenderness, erythema,
and induration) and systemic symptoms (malaise and/or fatigue,
myalgia, headache, nausea, vomiting, chills, arthralgia, and
temperature) were assessed.
Follow-up visits for clinical assessment, HIV risk reduction
counseling, and monitoring of safety and immunogenicity took
place at 14 days, 28 days, 3 months, 6 months, and 12 months
following vaccination. As part of the study’s safety evaluations,
HIV antibody screening using commercially available diagnostic
assay kits (Abbott HIVAB HIV 1/2 [rDNA], BioRad Genetic
Systems HIV 1/2 Plus O EIA, and/or bioMerieux Vironostika
HIV-1) as well as HIV RNA PCR assays were performed at the
last study visit.
T-cell immunogenicity was assessed by HIV-1-specific interfer-
on-gamma (IFN-c) enzyme-linked immunosorbent spot (ELISpot)
and intracellular cytokine staining (ICS) assays using cryopre-
served PBMC obtained at the predetermined endpoint of 28 days
post vaccination. IFN-c ELISpot responses were also assayed at
day 364. Assays for binding and neutralizing antibodies to HIV-1
were performed at day 28; binding antibody assays were also
performed at day 0.
Study Vaccine
VRC-HIVADV014-00-VP is a mixture of four replication-
deficient, recombinant serotype 5 adenoviral vectors. Each vector
expresses one of four HIV-1 antigens—clade B GagPol poly-
Candidate rAd5 HIV-1 Vaccine
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are combined in a 3:1:1:1 ratio, as previously described [8].
The four VRC-HIVADV014-00-VP recombinant adenoviral
vectors were constructed by subcloning HIV-1 DNA sequences
into an expression cassette in an E1-shuttle plasmid (AdFAST;
GenVec, Gaithersburg, MD). The GV11 adenoviral backbone
was chosen to reduce the risk of generating replication-competent
adenovirus during clinical production. The GV11 backbone
contains deletions of two essential regions, E1 and E4, as well as
a partial E3 deletion, which renders the vaccine product
replication deficient while providing increased transgene capacity
[14]. The 293-ORF6 cell line used to propagate these vectors was
developed by stably transforming HEK293 cells (of human
embryonic kidney origin) with an inducible E4-ORF6 expression
cassette, enabling the cells to efficiently complement the E1-, E4-,
and partial E3-deleted adenoviral vector [15,16].
The placebo consisted of the viral formulation buffer, composed
of sodium chloride, Tris buffer, trehalose (low endotoxin),
magnesium chloride, monooleate (Tween 80) and water for
injection.
Laboratory Methods
PBMC sample processing. Peripheral blood mononuclear
cells (PBMC) were processed and cryopreserved from whole blood
within 8 hours of venipuncture as previously described [17].
PBMC were thawed and rested overnight at 37uC/5% CO2 in
R10 [RPMI 1640 (Gibco/Invitrogen, Grand Island, NY)
containing 10% FCS (Gemini Bioproducts, West Sacramento,
CA), 2 mM L-glutamine (Gibco/Invitrogen), 100 U/ml penicillin
G, and 100 mg/ml streptomycin sulfate] prior to stimulation. A
minimum cell viability of 66% following the overnight rest was
required for assay by ELISpot and ICS.
Peptide stimulations. PBMC were assessed for ex vivo responses
with pools of HIV-1 15-mer peptides covering global potential T-
cell epitopes (PTE) representing HIV-1 peptides present in at least
15% of viral isolates in the Los Alamos database for Env, Gag, and
Pol [18]. Peptides for a given gene product (Env, Gag, Pol) were
pooled according to frequency, with pool one containing the most
frequent peptides for a given protein. A total of eight pools (three
for Env, two for Gag, and three for Pol), each containing no more
than 160 peptides at a final concentration of 1 mg/ml per peptide,
were used in this study. Response rates were measured for
responses to all eight peptide pools. The magnitudes of responses
were evaluated for pool 1 of Env, Gag and Pol, each containing
the 160 peptides of highest sequence frequency for these proteins.
For use as a positive non-HIV-1 antigen control, a pool of CMV
15-mer peptides overlapping by 11 amino acids spanning the
entire p65 protein (kindly provided by the Division of AIDS, NIH)
was also used.
For IFN-c ELISpot assays, PBMC were cultured for 18–
22 hours in 96-well plates with a PVDF membrane (Millipore
MultiScreen-IP Filter Plate; Millipore, Billerica, MA) at a density
of 200,000 cells in 125 ml R10 per well in the presence of the
peptide pools. PBMC without added peptide served as the
negative control, and phytohemagglutinin (PHA; Remel, Lenexa,
KS) stimulation served as the positive control.
For ICS assays, cells were cultured for six hours in 96-well U-
bottom plates at a density of one million cells per 200 ml well in the
presence of anti-CD28 and anti-CD49d antibodies (each at 1 mg/
ml; BD Biosciences, San Jose, CA), and Brefeldin A (10 mg/ml;
BD Biosciences). PBMC with peptide diluent (1% DMSO) served
as the negative control, and stimulation with 10 mg/ml staphylo-
coccal enterotoxin B (SEB; Sigma-Aldrich, St. Louis, MO) served
as a positive control.
Figure 1. CONSORT statement 2010 flow diagram. Precise enrollment screening numbers are not available due to the candidate pool being
screened for eligibility in multiple HVTN trials. Group 2 intervention proceeded only after a safety review of Group 1 interventions. For all analyses,
both placebo groups were combined into one pool. Numbers shown in the analysis row are maximum available, with some specific assays using
smaller numbers due to assay-specific losses, as detailed in the results.
doi:10.1371/journal.pone.0013579.g001
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been described previously [19]. Before stimulation, the wells were
coated with 100 mlo f1 0 mg/ml anti-human IFN-c antibody
(MabTech, Cincinnati, OH) in sterile phosphate-buffered saline
(PBS; GibcoBRL) for 15–24 hours at 4uC. The plates were then
washed with PBS, and PBMC were added and stimulated as
described above.Afterstimulation,the wells were washed withwash
buffer [PBS with 0.05% Tween 20 (Sigma-Aldrich)] and incubated
with 100 mlo f1mg/ml biotinylated anti-human IFN-c (MabTech)
in assay diluent [PBS with 0.5% bovine serum albumin (Sigma-
Aldrich)] for 2.5 hours. The wells were washed with wash buffer
and incubated with 100 ml of 1.33 mg/ml alkaline phosphatase-
conjugated anti-biotin antibody (Vector Laboratories, Burlingame,
CA)in assaydiluent for two hours.The wells werethen washed with
wash buffer and incubated with 100 ml of BCIP/NBT (Pierce,
Rockford, IL) for seven minutes, and then washed with deionized
water to stop color development. After drying overnight, the wells
were imaged and counted using a CTL Immunospot automated
plate reader with Immunospot software (version 3.1; Cellular
Technology Ltd., Cleveland, OH). Graphs were prepared using
JMP software (SAS Institute, Cary, NC).
Data from a given participant were excluded if they met any of
the following criteria: average response to PHA ,400 spot-
forming cells (SFC)/200,000 PBMC; average of negative control
wells .20 SFC/200,000 PBMC; day 2 viability less than 66%; or
blood obtained outside the allowable visit window. Data were also
excluded if the ratio of the variance of the experimental wells for a
specific peptide pool to [median+1] was $25.
ICS protocol. The ICS protocol has been described
previously [20]. The eight-color staining panel included the
following antibody-fluorophore conjugates: CD4 fluorescein, IL-2
phycoerythrin (PE), CD3 PE-Texas Red, CD8 PerCP-Cy5.5, IFN-
c PE-Cy7, IL-4 allophycocyanin (APC) and TNF-a Alexa-700 (all
except CD3 PE-TR from BD Biosciences; CD3 PE-TR from
Beckman-Coulter [Marseille, France]). The concentration of all
antibodies was optimized by titration studies prior to use. The
Cytokine Flow Cytometry (CFC) protocol from BD was used for
fixation and permeabilization. Briefly, after stimulation, cells were
stained with LIVE/DEAD Fixable Violet Dead Cell Stain (ViViD;
Molecular Probes/Invitrogen, Eugene, OR), fixed and frozen at
280uC. Cells were thawed within three weeks of freezing,
permeabilized and stained intracellularly. All samples were
acquired on an LSR II flow cytometer capable of measuring 18
colors (BD Biosciences), collecting 100,000–300,000 PBMC. A
High Throughput Sample Instrument (HTS; BD Biosciences) was
used to collect samples from 96-well plates. All FACS analyses
were performed using FlowJo software (version 6; Treestar,
Ashland, OR).
HIV-1 binding antibody assays. Standardized research
ELISAs were performed to delineate the antibody response to
viral antigens encoded within the vaccine. End-point titers of
antibodies were determined using 96-well Immulon2 (Dynex
Technologies) plates coated with a preparation of purified
recombinant HIV-1 proteins [21]. End-point titer was calculated
as the most dilute serum concentration that gave an optical density
reading of .0.2 above background.
Validated ELISAs were used to assess binding antibody
responses to p24Gag (Quality Biologicals) and MN gp120 (Protein
Sciences). Sera from cryopreserved samples were tested in
duplicate using microtiter plates (NUNC) coated with antigen.
Sera were diluted and incubated with the antigens bound to the
plate. The plates were washed with an automated and calibrated
plate washer (Bio-Tek) and read on an M2 plate reader (Molecular
Devices). Positivity was scored by duplicate antigen-containing and
non-antigen-containing wells (OD antigen – OD non-antigen) that
had an optical density (OD) greater than or equal to an OD of 0.2
after subtracting background. Standard curves were generated
from the plot of absorbance (450 nm) against the log of serum
dilution, and sigmoidal curves were fit using a four-parameter
logistic equation (Softmax Pro). The integrity of raw data
acquisition and data analyses were electronically tracked (21CFR
part 11 compliant) [22,23].
Although the validated ELISA assays used gp120 Env proteins
from laboratory-adapted HIV-1 strains, consensus gp140 envelope
sequences show greater similarity to the vaccine strains. Therefore,
after consensus gp140 envelope oligomers became available, we
re-tested stored sera for binding antibodies against these antigens.
Serum HIV-1 specific IgG responses (1/20 dilution) against ConS
gp140 CFI and BCon.env03 gp140 CF (provided by Dr. L. Liao,
Duke University) were measured by a standardized custom HIV-1
Luminex assay as previously described [23]. Antibody measure-
ments were acquired on a Bio-Plex instrument (Bio-Rad), output
as mean fluorescent intensity (MFI). The positive control in each
assay was an HIV
+ sera (HIV+16) standard curve (4PL fit) and the
negative control was IVIG and blank beads. Samples were
deemed positive if both the MFI and MFI minus blank were
greater than 3-fold over the baseline (study visit 2) MFI and
baseline MFI minus blank, respectively, and if the MFI minus
blank was at least 732 MFI (based on the average + 3 standard
deviations of 25 seronegative plasma samples).
HIV-1 neutralizing antibody assays. Neutralization was
measured as a function of reduction in luciferase reporter gene
expression after a single round of infection in TZM-bl cells as
described [24,25]. TZM-bl cells were obtained from the NIH
AIDS Research and Reference Reagent Program, as contributed
by John Kappes and Xiaoyun Wu. Briefly, 200 TCID50 of virus
was incubated with serial 3-fold dilutions of test sample in
duplicate in a total volume of 150 ml for one hour at 37uC in 96-
well flat-bottom culture plates. Freshly trypsinized cells (10,000
cells in 100 ml of growth medium containing 75 mg/ml DEAE
dextran) were added to each well. One set of control wells received
cells and virus (virus control) and another set received cells only
(background control). After incubation for 48 hours, 100 ml of cells
was transferred to 96-well black solid plates (Costar) for
measurement of luminescence using the Britelite Luminescence
Reporter Gene Assay System (PerkinElmer Life Sciences).
Neutralization titers are the dilution at which relative
luminescence units (RLU) were reduced by 50% compared to
virus control wells, after subtraction of background RLUs. Values
below the limit of detection (1:10 titer) were assigned a value of
one-half the lowest dilution tested (i.e., a value of 5) when
calculating geometric mean titer. Assay stocks of the molecularly
cloned Env-pseudotyped viruses Bal.26, 92rw020.2 and
97ZA012.29 were prepared by transfection in 293T cells and
were titrated in TZM-bl cells as described [25]. An assay stock of
HIV-1 MN was produced in H9 cells and titrated in TZM-bl cells.
Adenovirus neutralizing antibody screening. Pre-
vaccination sera were heat-inactivated and serially diluted in
supplemented Dulbecco’s modified Eagle’s medium. Optimized
concentrations of adenovirus type 5 or type 35 with a luciferase
reporter gene was added, followed by A549 human lung
carcinoma cells. The plates were then incubated at 37uC/10%
CO2 for 24 hours. The culture medium was aspirated, and cells
resuspended in Glo Lysis Buffer (Promega). The cell suspensions
were transferred to a Black and White isoplate (Perkin Elmer) and
Steady-Glo Luciferase Assay System Reagent (Promega) was
added to the wells. The luminescence was measured on a
luminometer. Neutralizing titer was defined as the highest titer
Candidate rAd5 HIV-1 Vaccine
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without sera. Atypical control results invalidated an entire assay
run. A titer of ,1:12 was considered negative [26].
Statistical Methods
The sample size of 20 vaccine and four placebo recipients per
group provided a 90% chance of observing at least one serious
adverse experience if the true rate of such an event were at least
11%; there was a 90% chance that we would not observe at least
one serious adverse experience if the true rate was no more than
0.5%. The precision to estimate immunogenicity was somewhat
limited and therefore not a primary objective of the study. The
width of a two-sided 95% confidence interval for each vaccine
group was at most 0.44; for a 50% response rate, the 95% CI was
approximately (0.28, 0.72).
Kruskal-Wallis tests were performed to compare severity of
reactogenicity symptoms among the three groups. If the resulting
p-value indicated a significant difference among the groups,
further testing (Kruskal-Wallis) was then done to compare severity
of reactogenicity symptoms in the two active treatment groups. To
account for the multiple testing in these latter comparisons, the
Simes procedure was used to control the false discovery rate at
0.05 [27]. The procedure was implemented separately for the local
and systemic reactogenicity symptom comparisons.
To summarize the T-cell response data, positive response rates
to any peptide pool and to each individual peptide pool were
reported. Positivity of the individual IFN-c response by ELISpot
was determined by a one-sided bootstrap test of the null hypothesis
that the responses in the experimental wells were twice those of the
background (a=0.05) [28]. A Westfall-Young approach [29] was
used to adjust for the multiple comparisons across peptide pools.
Peptide pools with adjusted one-sided p-values #0.05 were
declared positive. In addition, the mean difference in the
experimental and negative control wells had to exceed 50 SFC
per 10
6 PBMC for the response to be positive.
Positive responses were determined in the ICS assay by a one-
sided Fisher’s exact test applied to each response to a peptide pool
vs. the response to the negative control with a discrete Bonferroni
adjustment for the multiple comparisons. Peptide pools with
adjusted p-values less than a=0.00001 were considered positive.
Positivity was determined for the combined cytokine subset: IFN-
c
+ and/or IL-2
+. If at least one cytokine subset was positive, the
overall peptide pool was considered positive.
Confidence intervals for response rates were calculated with
Agresti and Coull’s method [30].
SAS (version 9.1; SAS Institute) and Splus (version 6.0;
Insightful) were used for all analyses.
Results
Enrollment and Follow Up
Forty-eight participants consented, enrolled, and received their
assigned injection at study entry between the months of April and
September 2005, in two sequential groups to permit dose
escalation. Data from placebo recipients in both groups were
pooled in the analysis. As shown in Table 1, demographic
characteristics were comparable among the treatment groups.
The analysis was by intention to treat, modified to exclude
individuals who entered in the randomization process but did not
proceed with study enrollment; five such individuals were not
included in the analysis. All 48 participants provided data for the
reactogenicity assessments and blood samples for the primary
immunogenicity analyses at day 28. Forty-six of the 48 participants
(96%) completed planned follow up through one year post
injection. The remaining two participants (one each in the 10
10
PU and 10
11 PU groups) relocated away from study sites prior to
the one-year follow-up (Figure 1).
Safety
No serious adverse events (such as permanent disability or
incapacity, life-threatening medical conditions, or deaths) and no
HIV infections occurred among study participants. Of 48
participants, 46 reported one or more adverse event as of the
final study visit; the majority of these events were mild in severity
and not related to study treatment. Treatment-associated events
that were graded as severe by study staff occurred in four
Table 1. Demographic characteristics of the study groups.
Placebo (N=8) 10
10 PU (N=20) 10
11 PU (N=20) Total (N=48)
Sex
Male 2 (25%) 14 (70%) 11 (55%) 27 (56%)
Female 6 (75%) 6 (30%) 9 (45%) 21 (44%)
Age in years
Median 27.0 28.0 27.5 27.5
Range 20–37 20–48 20–50 20–50
Race/Ethnicity
White* 5 (63%) 17 (85%) 15 (75%) 37 (77%)
African-American* 1 (13%) 0 2 (10%) 3 (6%)
Hispanic 0 1 (5%) 0 1 (2%)
Native American/Alaskan 1 (13%) 0 0 1 (2%)
Multiracial/Other 1 (13%) 2 (10%) 3 (15%) 6 (12%)
Sexual orientation
Heterosexual 6 (75%) 9(45%) 11 (55%) 26 (54%)
Homo/bisexual 2 (26%) 11 (55%) 9 (45%) 22 (45%)
*Non-Hispanic.
doi:10.1371/journal.pone.0013579.t001
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or more of the following: fever, chills, malaise, myalgia, fatigue,
and/or headache. These symptoms occurred within 24 hours
following injection of the 10
11 PU dose and improved noticeably
within 48 hours. The two additional adverse events rated severe
(one viral syndrome occurring 201 days post vaccination, and one
episode of low back pain, both in vaccine recipients) were reported
as not related to study treatment.
Adverse events associated with vaccine treatment and beginning
within 72 hours of injection are reported in Tables 2 (local
reactions) and 3 (systemic reactions), which summarize the
maximum severity during the reactogenicity period of a given
symptom, sign, or specified combination in a given participant.
Local reactogenicity occurred with greater severity in vaccine
recipients than in placebo recipients (Table 2), but no significant
difference was detected between the two vaccine dose levels. Seven
of the nine systemic reactogenicity outcomes (malaise and/or
fatigue, myalgia, headache, chills, arthralgia, maximum systemic
symptom, and fever) occurred with greater severity in the higher
dose (10
11 PU) group than in the lower dose (10
10 PU) group
(Table 3), and were usually graded mild to moderate when they
occurred. Figure 2 shows, for each dosing group, the intensity of
all participants’ maximum systemic reactogenicity symptom on
each day of the reactogenicity period, indicating that these
symptoms tended to peak by day 1 following injection, and that
most resolved by day 3.
Clinical laboratory monitoring of blood samples revealed no
significant changes in safety parameters following vaccination. All
laboratory abnormalities were graded as mild except three
elevations in creatine phosphokinase graded as moderate, all of
Table 2. Maximum local reactogenicity.
Treatment – n (%) Unadjusted p*
Symptom or sign** Placebo (N=8) 10
10 PU (N=20) 10
11 PU (N=20) Total (N=48)
(Kruskal-Wallis)
10
10 vs. 10
11PU
Pain 0.2726
None 8 (100) 9 (45) 5 (25) 22 (45.8)
Mild 0 8 (40) 11 (55) 19 (39.6)
Moderate 0 3 (15) 4 (20) 7 (14.6)
Severe 0000
Tenderness 0.0967
None 6 (75) 4 (20) 2 (10) 12 (25)
Mild 2 (25) 13 (65) 10 (50) 25 (52.1)
Moderate 0 3 (15) 8 (40) 11 (22.9)
Severe 0000
Pain and/or tenderness 0.1230
None 6 (75) 4 (20) 0 10 (20.8)
Mild 2 (25) 11 (55) 12 (60) 25 (52.1)
Moderate 0 5 (25) 8 (40) 13 (27.1)
Severe 0000
Erythema 0.0796
None 8 (100) 19 (95) 14 (70) 41 (85.4)
.0t o1 0c m
2 0 1 (5) 5 (25) 6 (12.5)
.10 to 25 cm
2 0000
.25 cm
2 0 0 1 (5) 1 (2.1)
Induration 0.0335
None 8 (100) 19 (95) 13 (65) 40 (88.3)
.0t o1 0c m
2 0 1 (5) 5 (25) 6 (12.5)
.10 to 25 cm
2 0 0 1 (5) 1 (2.1)
.25 cm
2 0 0 1 (5) 1 (2.1)
Erythema and/or induration 0.0435
None 8 (100) 18 (90) 12 (60) 38 (79.2)
.0t o1 0c m
2 0 2 (10) 6 (30) 8 (16.7)
.10 to 25 cm
2 0 0 1 (5) 1 (2.1)
.25 cm
2 0 0 1 (5) 1 (2.1)
*For each local reactogenicity outcome, a statistically significant difference was found among the three treatment arms (Kruskal-Wallis p #0.05; values not shown).
Unadjusted P values specifically for 10
10 PU vs. 10
11 PU arms (shown in table) were subsequently calculated. None of these are significant after applying Simes
procedure to control the false discovery rate at 0.05 to account for the multiple comparisons.
**Mild: Pain/tenderness causing no or minimal limitation of use of limb; Moderate: pain/tenderness limiting use of limb or causing greater than minimal interference
with usual social & functional activities; Severe: pain/tenderness causing inability to perform usual social & functional activities.
doi:10.1371/journal.pone.0013579.t002
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Treatment – n (%) Unadjusted p*
Symptom or sign** Placebo (N=8) 10
10 PU (N=20) 10
11 PU (N=20) Total (N=48)
(Kruskal-Wallis)
10
10 vs. 10
11PU
Malaise and/or fatigue 0.0245
None 5 (62.5) 6 (30) 4 (20) 15 (31.3)
Mild 2 (25) 9 (45) 3 (15) 14 (29.2)
Moderate 1 (12.5) 5 (25) 9 (45) 15 (31.3)
Severe 0 0 4 (20) 4 (8.3)
Myalgia 0.0039
None 6 (75) 12 (60) 5 (25) 23 (47.9)
Mild 2 (25) 6 (30) 4 (20) 12 (25.0)
Moderate 0 2 (10) 9 (45) 11 (22.9)
Severe 0 0 2 (10) 2 (4.2)
Headache 0.0073
None 4 (50) 13 (65) 5 (25) 22 (45.8)
Mild 4 (50) 6 (30) 9 (45) 19 (39.6)
Moderate 0 1 (5) 5 (25) 6 (12.5)
Severe 0 0 1 (5) 1 (2.1)
Nausea NS
None 7 (87.5) 17 (85) 13 (65) 37 (77.1)
Mild 1 (12.5) 3 (15) 4 (20) 8 (16.7)
Moderate 0 0 3 (15) 3 (6.3)
Severe 0 0 0 0
Vomiting NS
None 8 (100) 20 (100) 9 (95) 47 (97.9)
Mild 0 0 1 (5) 1 (2.1)
Moderate 0 0 0 0
Severe 0 0 0 0
Chills ,0.0001
None 8 (100) 20 (100) 8 (40) 36 (75)
Mild 0 0 6 (30) 6 (12.5)
Moderate 0 0 3 (15) 3 (6.3)
Severe 0 0 3 (15) 3 (6.3)
Arthralgia 0.0136
None 7 (87.5) 18 (90) 10 (50) 35 (72.9)
Mild 1 (12.5) 1 (5) 9 (45) 11 (22.9)
Moderate 0 1 (5) 1 (5) 2 (4.2)
Severe 0 0 0 0
Maximum systemic symptoms 0.0027
None 2 (25) 6 (30) 2 (10) 10 (20.8)
Mild 5 (62.5) 8 (40) 3 (15) 16 (33.3)
Moderate 1 (12.5) 6 (30) 11 (55) 18 (37.5)
Severe 0 0 4 (20) 4 (8.3)
Temperature (uC) 0.0052
34.0–37.6 8 (100) 19 (95) 11 (55) 38 (79.2)
37.7–38.6 0 1 (5) 5 (25) 6 (12.5)
38.7–39.3 0 0 3 (15) 3 (6.3)
39.4–40.5 0 0 1 (5) 1 (2.1)
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to study treatment. To screen for the theoretical possibility of
recombination between vaccine product and circulating adenovi-
ruses, swab cultures were performed on participants reporting
symptoms of upper respiratory infection or conjunctivitis within
four weeks following study injection. Of two conjunctival and 18
throat cultures taken, all were negative for adenovirus.
When participants completed study visits, they were tested with
commercially available HIV antibody tests to inform them about
the likelihood of testing positive for antibodies if tested outside of
the study site. Of those with commercial HIV antibody testing
results available at 12 months following injection, 18/19
participants who received the 10
10 PU dose, 15/19 who received
the 10
11 PU dose, and 0/8 placebo recipients tested positive for
HIV antibodies by at least one of three commercially available
enzyme immunoassays. The majority (87% of vaccine recipients)
had vaccine-induced antibody responses detected by the Abbott
HIVAB HIV 1/2 diagnostic assay. Lower antibody response rates
were seen with the BioRad Genetic Systems HIV 1/2 Plus O EIA
(11%) and bioMerieux Vironostika HIV-1 (8%) diagnostic assays.
T-Cell Immunogenicity
In IFN-c ELISpot assays at day 28 post vaccination, 14/16
(88%) of participants who received the 10
10 PU dose, 17/20 (85%)
of those who received the 10
11 PU dose, and 0/7 placebo
recipients mounted HIV-1-specific T cell responses to at least one
antigen pool (Figure 3). Data at day 28 from five participants (one
in the placebo group and four in the 10
10 PU group) could not be
analyzed because of poor cell viability or high assay background
levels. Of the 36 vaccine recipients with ELISpot data, 64% had
PBMC that recognized more than one of the vaccine antigens
(Gag, Pol, or Env) and 47% recognized all three antigens at day
28. Two of 19 (11%) participants in the 10
11 PU group also had
positive IFN-c ELISpot responses at day 0, but both individuals
showed responses to a larger number of antigens at day 28 (data
not shown). The proportion of vaccine recipients responding to a
given antigen pool at day 28 ranged between 50% and 88% of
assayable participants, depending on pool and vaccine dose.
Persistent T-cell responses from PBMC collected at day 364
following vaccination were observed at both vaccine doses and
remained distributed across all three HIV-1 antigens (Figure 3).
By ICS analysis, both CD4
+ and CD8
+ T cell responses were
detectable (representative high and low positive samples shown in
Figure 4). HIV-specific CD4
+ T cells were distributed among cells
co-producing IFN-c and IL-2, and cells producing IFN-c without
IL-2 or IL-2 without IFN-c. HIV-specific CD8
+ T cells largely
produced IFN-c without IL-2, although some cells co-producing
both cytokines were detected. Examining the overall CD4
+ or
Treatment – n (%) Unadjusted p*
Symptom or sign** Placebo (N=8) 10
10 PU (N=20) 10
11 PU (N=20) Total (N=48)
(Kruskal-Wallis)
10
10 vs. 10
11PU
40.6 or greater 0 0 0 0
*For each systemic reactogenicity outcome except nausea and vomiting (NS: not significant), a statistically significant difference was found among the three treatment
arms (Kruskal-Wallis p #0.01; values not shown). For those outcomes showing an overall significant difference, unadjusted p values specifically for 10
10 PU vs. 10
11 PU
arms (shown in table) were subsequently calculated. All of these are significant after applying Simes procedure to control the false discovery rate at 0.05 to account for
the multiple comparisons.
**Severity definitions are given in the HVTN Table for Grading Severity of Adverse Experiences (Revised Sep 2002); see also Division of AIDS Table for Grading the Severity of
Adult and Pediatric Adverse Events (December, 2004). In general, mild systemic reactions are those causing no or minimal interference with usual social and functional
activities; moderate reactions cause greater than minimal interference with such activities; and severe reactions cause inability to perform such activities.
doi:10.1371/journal.pone.0013579.t003
Table 3. Cont.
Figure 2. Duration and intensity of systemic reactogenicity. Number of vaccine recipients experiencing each level of severity in one or more
systemic symptoms (malaise and/or fatigue, myalgia, headache, nausea, vomiting, chills, or arthralgia) is shown at baseline and for each day of the
reactogenicity period. Panel A: 10
10 PU dose; Panel B: 10
11 PU dose. Only the most severe symptom level for each individual on each day is included.
doi:10.1371/journal.pone.0013579.g002
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+ T-cell response, ICS analyses detected vaccine responses in
60–90% of vaccine recipients according to antigen pool (Figure 5).
The proportion of participants with CD8
+ T-cell responses was
comparable, but nominally higher, than those with CD4
+ T-cell
responses. At day 28, CD8
+ T-cell responses (to any peptide pool,
and for IFN-c or IL-2 detection) were found in 17/18 (94%; 95%
CI: 74–99%) of participants in the 10
10 PU dose group with CD8
+
ICS data and in 17/20 (85%; 64–95%) of those in the 10
11 PU
dose group; CD4
+ T-cell responses were found in 16/19 (84%; 62-
95%) of participants in the 10
10 PU dose group with CD4
+ ICS
data and in 11/20 (55%; 34–74%) of those in the 10
11 PU dose
group. Two vaccinees in the 10
10 PU dose group were excluded
from the CD8
+ analysis, one due to high background and one due
to low numbers of T cells (this participant was also excluded from
the CD4
+ analysis due to low numbers of T cells). At day 28, T-cell
responses in both CD4
+ and CD8
+ subsets were detected in 26 of
38 (68%) vaccine recipients with specimens for both subsets. Of
these 26, two vaccine recipients had positive ICS responses in both
T cell subsets at day 0, but both individuals showed responses to a
larger number of antigens at day 28 (data not shown).
The frequency and specificity of T-cell responses, assessed by
ELISpot and ICS assays, appeared similar at both vaccine doses,
but the study was not sufficiently powered to formally compare
dose groups.
HIV-1 antigen-specific response magnitudes at day 28 for the
IFN-c ELISpot assay are shown in Figure 6, and for ICS assays in
Figure 7A (CD4
+ T-cell responses) and 7B (CD8
+ T-cell
responses). In the IFN-c ELISpot assay, median response
magnitudes ranged between approximately 150 and 800 SFC/
10
6 PBMC according to antigen pool. In the ICS analyses, median
percentages of T cells showing IFN-c or IL-2 responses at day 28
to each of the three antigens in each of the two vaccine dose
groups ranged from approximately 0.05% to 0.15% (CD4
+ T-cell
responses) and from approximately 0.1% to 0.7% (CD8
+ T-cell
responses) according to antigen (Figures 7A and 7B).
Of the 39 participants with detectable HIV-1-specific CD4
+ T-
cell responses to any PTE pool by ICS on day 28, 18 (46%) had
responses detected in the IFN-c
+IL-2
+ subset, 9 (23%) had IL-
2
+IFN-c
2 responses, and 9 (23%) had IFN-c
+IL-2
2 responses. Of
the 38 participants with HIV-1-specific CD8
+ T-cell responses, 21
(55%) had responses in the IFN-c
+IL-2
+ subset, none had IL-
2
+IFN-c
2 responses, and 32 (84%) had responses in the IFN-c
+IL-
2
2 subset (data not shown).
Antibody Immunogenicity
Sera from days 0 and 28 were evaluated by multiple assays for
HIV-1-specific antibodies. Using an endpoint dilution ELISA, sera
from 0/8 placebo recipients were positive for antibodies against
any tested vaccine-encoded HIV-1 antigen, and 19/20 (95%) in
each of the 10
10 PU and 10
11 PU dose groups were positive to one
or more vaccine-encoded HIV-1 antigen (clade A, B, or C Env;
clade B Gag, Pol, or Nef). Antibody response rates to Env antigens
were most frequent, ranging from 75% to 95% of participants
across clades and doses, with geometric mean titer (GMT) ranging
Figure 3. T-cell responses to HIV antigens by IFN-c ELISpot. Points indicate percentage of participants with positive responses; n denotes the
number in each group with ELISpot data. Lines indicate 95% confidence intervals.
doi:10.1371/journal.pone.0013579.g003
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Gag (20% and 45% of participants in the 10
10 PU and 10
11 PU
groups, respectively, with GMT 90 in both dose groups) and Pol
(15% and 5%, with GMTs 30 and 90 respectively) appeared to be
less frequent. Antibody responses to Nef, which was not included
in the vaccine, were minimal (15% [GMT 30] in the 10
10 PU
group and 0% in the 10
11 PU group).
Another ELISA for binding antibodies against laboratory-
adapted HIV-1 gp120 Env and p24 Gag proteins showed sera
from 0/8 placebo recipients, 0/20 participants in the 10
10 PU dose
group and 2/20 (10%) in the 10
11 PU dose had an elevation in
anti-Gag antibodies at day 28 after vaccination, while no
participants were positive for antibodies against the gp120 antigen.
Using a more sensitive flow cytometry-based multiplex assay and
consensus envelope antigens, sera from 0/7 placebo recipients,
14/20 (70%) participants in the 10
10 PU dose group and 15/20
(75%) in the 10
11 PU dose group were positive for antibodies
against Bcon.env03 gp140 CF; 0/7 placebo recipients and 20/20
vaccine recipients at both dose levels were positive for antibodies
against ConS gp140 CFI. Among positive responders, geometric
mean fluorescence for Bcon.env03 gp140 CF was 5008 (3925 in
the 10
10 PU dose group and 6286 in the 10
11 PU dose group) and
geometric mean fluorescence for ConS gp140 CFI was 9074 (7966
in the 10
10 PU dose group and 10336 in the 10
11 PU dose group).
Functional activity of the vaccine-induced antibodies was assessed
in a neutralizing assay. Neutralizing activity against HIV-1 strain
Figure 4. Staining profiles for ICS analysis for two trial participants. The expression of IFN-c and IL-2 are shown for CD4
+ and CD8
+ T cells in
response to stimulation with the first pools for Env, Gag, and Pol and for the negative control (peptide diluent, 1% DMSO) at day 28. Numbers on the
plots are the percentages of CD4
+ or CD8
+ T cells producing the cytokine or combination of cytokines. Participant 1 represents an example of a high
CD8
+ T-cell response and Participant 2 represents low CD4
+ and CD8
+ T-cell responses. All responses are positive as tested for cells producing IFN-c
and/or IL-2 except for Env and Pol for participant 2. Both participants were in the 10
11 PU dose group.
doi:10.1371/journal.pone.0013579.g004
Candidate rAd5 HIV-1 Vaccine
PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13579MN was minimal. At day 28, 2/8 placebo recipients (25%, GMT
=12), 13/20 from the 10
10 PU dose group (65.0%, GMT =23),
and 1/20 from the 10
11 PU group (5.0%, GMT =6) had
detectable responses.
Discussion
In this randomized, double-blind, placebo-controlled clinical
trial, the multiclade, multiprotein rAd5 HIV-1 vaccine VRC-
HIVADV014-00-VP appeared safe and was highly immunogenic
among participants seronegative for prior nAb to Ad5. This study
extends the prospective safety testing of recombinant type 5
adenoviral vectors specifically to include Ad5-seronegative volun-
teers, and provides evidence that in this group the 10
10 PU dose is
of comparable immunogenicity to, and better tolerated than, the
10
11 PU dose.
A single dose of the vaccine induced T-cell responses against all
three HIV-1 proteins encoded by the vector. Responses to one or
more antigen pools were detected in 85% to 95% of vaccine
recipients. Among responders, median ELISpot response magni-
tudes were on the order of several hundred SFC/10
6 PBMC, and
ICS detected CD4
+ and CD8
+ T-cell responses on the order of
0.1% to 1% of T cells. Sixty-five percent of vaccinees showed
responses in both CD4
+ and CD8
+ T cell subsets at 28 days post
vaccination. Responses in individual participants reached magni-
tudes of up to 3000 SFC/10
6 PBMC in the IFN-c ELISpot assay
and up to 4% of total CD8
+ T cells in the ICS assay. The majority
of vaccinees (,80%) had IFN-c-secreting, HIV-1-specific T cells
persisting at one year post vaccination. Responses to Pol were
observed at higher frequencies than reported in previous in trials
that used a DNA-prime/rAd5 boost regimen, as discussed below.
All vaccinees (and no placebo recipients) developed binding
antibodies against a consensus HIV-1 gp140 oligomer at day 28.
The vaccine also induced binding antibodies against vaccine
antigens (but not against gp120 antigens from laboratory-adapted
HIV-1 strains) in the majority of recipients, and induced
neutralizing antibodies at low titers in approximately half of
participants in the lower dose group.
Given the diversity of circulating HIV strains and the rapidity
with which variants arise within infected individuals, a vaccine’s
ability to induce a broad response across viral proteins may be
important to the success of a T cell-based vaccine strategy. In this
study, three quarters of vaccinees developed T-cell responses to
two or more HIV-1 antigens detectable by stimulation with pools
of global potential T-cell epitopes. The induction of both IL-2 and
IFN-c secreting cells among the CD4
+ and CD8
+ T-cell
populations responding to the vaccine indicates that the vaccine
induces T cells representing a variety of functional characteristics,
including both MHC class I-restricted cytotoxic and class II-
restricted helper cells.
A Phase IIb proof-of-concept trial (the Step study) evaluating an
HIV-1 gag/pol/nef vaccine using a different adenoviral vector
developed by Merck Research Laboratories was stopped early
after an interim efficacy analysis found the vaccine to be
Figure 5. T-cell responses to HIV antigens by ICS. Points indicate percentage of participants with positive responses (for CD4
+ or CD8
+ T cell
subsets, and for IFN-c or IL-2 detection); n denotes the number in each group with ICS data. Lines indicate 95% confidence intervals.
doi:10.1371/journal.pone.0013579.g005
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responses [31]. Moreover, although in that study no statistically
significant differences in incidence of HIV infection were observed
in the vaccine vs. placebo group, based on exploratory subgroup
analyses uncircumcised men with prior Ad5 nAbs have been
excluded in further trials with Ad5. Of note, unlike the VRC Ad5
vaccine investigated in the current study and the canarypox vector
that was used in the Thai trial, the Merck vaccine did not include
HIV Env antigens. Although immune correlates of protection in
the Thai trial are not yet known, that study found CD4
+ T cell and
antibody responses against HIV Env antigen in vaccine recipients
[2]. In addition, the specific deletions (E1, E3, E4) used to render
the VRC adenovector replication defective may have different
effects on vaccine immunogenicity compared to the E1-deleted
Merck vector. The addition of the E4 deletion has been found in
vitro to result in lower levels of rAd5 expression than seen in E1,E3-
deleted vectors, and an E1,E3,E4-deleted vector did not prevent
vaccine ‘‘take’’, as measured by increases in Ad5 neutralizing
antibodies four weeks following vaccination in volunteers with
prior Ad5 nAb [32].
The immune responses following a single injection in the
current study (which was performed before the results of the Step
study became available) appear to compare favorably with
responses in studies of multiple dose regimens of adenovectors
alone or in combination with DNA plasmids, but there are some
differences. For example the Step study [19,31] of three doses of
an HIV-1 gag/pol/nef Ad5 vaccine found HIV-specific T cells
recognizing one or more gene products in 86% of participants
with Ad5 titers #200, with geometric mean ELISpot response
magnitudes in the range of several hundred SFC/10
6 PBMC at
week 8, the primary immunogenicity time point [19]. Similarly,
analyses of T-cell responses from clinical trial subjects who
received Merck vaccine candidates that included an HIV-1 gag
insert – either by DNA priming followed by rAd5 boosting, or by a
homologous rAd5/rAd5 prime-boost regimen – found IFN-c
ELISpot response rates of 42% to 65% in subjects not stratified by
prior Ad5 immunity, with evidence of higher response rates in
those with prior Ad5 Nab titers ,1:200 [33,34]. In an
international Phase IIa study of a three-injection DNA plasmid
priming series followed by a single boost with VRC-HIVADV014-
00-VP (HVTN study 204), T-cell responses to Env and Gag
peptides were seen in approximately half of participants, twice as
many as responded to Pol [35]. Similarly, an East African Phase I/
II study that compared a prime-boost regimen using the same
DNA and rAd5 products to rAd5 alone found T-cell responses to
Env to be several times more frequent than those to Pol following
the prime-boost regimen, while rAd5 alone elicited more frequent
responses to Pol (and less frequent responses to Gag) than did the
DNA prime/rAd5 boost regimen [36,37]. These results raise the
possibility that the prominent responses to Pol seen in the current
study, as well as in the much larger Step study [31], may be
associated with the use of an adenoviral vector alone, and that
choice of vaccine vector or prime-boost regimen, or both, may
affect the relative responses to different vaccine antigens.
The high (approximately 85%) rate of vaccine-induced antibody
responses detected by the Abbott HIV diagnostic assay even 12
months following vaccination, and lower (but non-zero) rates with
BioRad and bioMerieux diagnostic assays illustrate the importance
of appropriate screening algorithms for HIV infection in the
setting of vaccine trials, as participants obtaining routine antibody
screening outside of the study site are at risk of unblinding, or
facing uninterpretable or false-positive results. In this study,
participants were counseled throughout the trial not to obtain HIV
testing outside of the clinical research units, which provided HIV
Figure 6. Magnitudes of T-cell responses to pool 1 global PTE peptides, measured by IFN-c ELISpot assay. Day 0 (left column) is a
combined analysis including responses from PBMC from placebo recipients; day 28 (remaining columns) is sorted by HIV-1 gene product. The box
plots are based only on the positive responses. The box indicates the median and interquartile range (IQR); whiskers extend to the furthest point
within 1.5 times the IQR from the upper or lower quartile. The number of vaccinees with a positive response out of the total number of vaccinees
tested is indicated above the bars.
doi:10.1371/journal.pone.0013579.g006
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between vaccine-induced seropositivity and actual HIV infection.
Although anti-Env binding and neutralizing antibodies were
elicited with the VRC Ad5 vaccine, these responses were low in
titer and not broadly neutralizing. They are lower than antibody
responses induced by DNA priming prior to rAd5 boosting, vector
prime and Env gp120 subunit protein boosts, and Env subunit
boost alone [22,38,39,40].
Figure 7. Magnitudes of responses by ICS to pool 1 peptides at day 28 following study injection. A) CD4
+ T cell responses. B) CD8
+ T cell
responses. The box plots are based only on the positive responses. The box indicates the median and interquartile range (IQR); whiskers extend to the
furthest point within 1.5 times the IQR from the upper or lower quartile. The number of vaccinees with a positive response out of the total number of
vaccinees tested is indicated above the bars.
doi:10.1371/journal.pone.0013579.g007
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seronegative study population, which, although intended to
provide optimal sensitivity for assessing the safety of the vaccine
in a small study population, would be expected to result in more
frequent or higher magnitude T-cell responses than would be
anticipated in volunteers with substantial pre-existing nAb
immunity to Ad5. It is therefore not possible to extrapolate these
results to individuals with prior antibody immunity to Ad5.
However, larger studies indicate that vector immunity attenuates,
but does not eliminate, immune responses. In earlier dose-
escalation clinical trials of HIV-1 clade B gag Ad5 monovalent [41]
and HIV-1 gag/pol/nef Ad5 trivalent [42] vaccines developed by
Merck Research Laboratories, the frequency of injection-site
reactions as well as systemic adverse effects was dose dependent,
and systemic effects (but not local reactions) occurred more
frequently in subjects with baseline Ad5 nAb titers ,1:200. The
proportion of vaccine recipients mounting IFN-c-secreting T cells
recognizing HIV-1 antigens, and the magnitudes of these
responses, were generally higher in those with lower baseline
Ad5 nAb titers. However, the effect of prior vector immunity on
vaccine response in these studies was diminished at higher doses
[41], although not uniformly [42]. While response rates and
magnitudes in Step participants with Ad5 titers #1:18 appeared
comparable to those with titers #1:200, responses in those with
titers .1:200 appeared somewhat lower [19]. Analysis of immune
responses from a Phase IIa clinical trial of a prime-boost regimen
consisting of DNA plasmids followed by VRC-HIVADV014-00-
VP (HVTN study 204) found that preexisting Ad5 neutralizing
antibodies blunted both CD4
+ and CD8
+ T-cell responses to Gag,
but did not produce a significant effect on Env responses [43].
Additional limitations of this study include its modest sample
size, which leaves open the possibility of infrequent vaccine-
associated adverse events that might be observed in a larger study,
and the enrollment of participants at only US sites, where self-
reporting of safety outcomes may differ from that in other
locations.
To the extent that prior Ad5 nAb immunity dampens vaccine-
induced T-cell responses, such an effect might potentially be
addressed by priming with other viral vectors or with DNA
plasmids followed by boosting with an Ad5 vector [36,44], or by
developing adenoviral vectors of alternative serotypes to which
prior antibody immunity is less frequent. In any of these
approaches, predicting the vector dose that optimizes safety,
particularly in vector-naı ¨ve individuals, yet provides optimal
immunogenicity will facilitate the design of clinical trials.
The current study supports the clinical tolerability of adenoviral
vector vaccines in the absence of prior vector nAb immunity, and
shows that a single, well tolerated 10
10 PU dose of the VRC
adenoviral vector can produce T-cell responses of high magnitude,
breadth and durability, high-frequency CD8
+ and CD4
+ T-cell
responses, as well as antibody responses, against HIV-1 antigens.
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